Get notified when PFE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — The filing references a CFO transition disclosed on the same day, indicating a leadership change in the finance function.
Pfizer reaffirms FY2026 guidance ($59.5-$62.5B revenue, $2.80-$3.00 EPS) amid CFO transition
Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read
Key Changes
-
high
Pfizer reaffirmed full-year 2026 revenue guidance of $59.5-$62.5 billion and adjusted EPS of $2.80-$3.00, unchanged from December 2025 and May 2026 targets, following CFO transition announcement.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
medium
CFO transition disclosed June 18, 2026; management signals confidence the leadership change will not disrupt financial trajectory or operational execution.
Item 7.01 — Regulation FD Disclosure verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NAVI 10-Q) is open in full — no account needed.
Partner
Trade PFE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 20, 2026 · How we verify